Trials / Completed
CompletedNCT04869670
A Study to Evaluate Safety and Effectiveness of G-POEM for Gastroparesis
A Pilot and Feasibility Trial of G-POEM for Gastroparesis to Assess Safety, Physiological Mechanisms and Efficacy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to evaluate the 12-month treatment effect of peroral endoscopic pyloromyotomy (G-POEM) vs. sham surgery in patients with gastroparesis that is not helped by medications and to analyze factors that may predict the outcome of the surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Gastric peroral endoscopic myotomy. | Under propofol anesthesia, EndoFLIP will be used to assess pyloric diameter and distensibility, prior to and after G-POEM, performed by an endoscopist skilled in this technique. After the procedure, the patient will be observed in the hospital for 2 days. Patients will undergo an upper GI series the next day to rule out perforation. If the patient develops a complication from the procedure, he or she will be managed per standard clinical practice by the treating (unblinded) endoscopist. |
| PROCEDURE | Sham Gastric peroral endoscopic myotomy. | Patients assigned to the sham procedure will be treated identically as above, except for the performance of the G-POEM. Endoscopy and EndoFLIP will be performed and sedation will be stopped when the upper endoscopy is completed. Since sham endoscopy is expected to take less time than G-POEM, the patient should remain in the endoscopy procedure room for a minimum of 30 minutes (including the time required to complete the upper endoscopy). After the procedure, the patient will be observed in the hospital for 2 days. All patients will undergo an upper GI series radiographic examination the next day to rule out perforation in order to maintain study blind. |
Timeline
- Start date
- 2023-07-12
- Primary completion
- 2025-03-03
- Completion
- 2025-03-03
- First posted
- 2021-05-03
- Last updated
- 2025-03-05
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04869670. Inclusion in this directory is not an endorsement.